Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-Pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-Pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

Democrats Push Biden to Issue Executive Orders on Drug Pricing, COVID-19 IP

  • Post author:PacConAdmin
  • Post published:March 20, 2022
  • Post category:Drug Industry Daily

There’s a push by congressional Democrats to get President Biden to issue a host of executive orders as soon as possible on key priorities, including drug pricing, because they’re not…

Continue ReadingDemocrats Push Biden to Issue Executive Orders on Drug Pricing, COVID-19 IP

Moderna and Pfizer Push for EUAs for Fourth Booster; Study Questions its Effectiveness

  • Post author:PacConAdmin
  • Post published:March 20, 2022
  • Post category:Drug Industry Daily

Moderna and Pfizer/BioNTech are both pushing to get expanded Emergency Use Authorization (EUA) for a fourth dose/second booster of their COVID-19 vaccines, but a new study questions its effectiveness in…

Continue ReadingModerna and Pfizer Push for EUAs for Fourth Booster; Study Questions its Effectiveness

PhRMA Supports Diversity in Trials, Balks at Mandates

  • Post author:PacConAdmin
  • Post published:March 20, 2022
  • Post category:Drug Industry Daily

Diversity is a critical area in clinical research that desperately needs to be improved, the pharma industry agrees, but policies that would require sponsors to enroll more diverse populations will…

Continue ReadingPhRMA Supports Diversity in Trials, Balks at Mandates

AstraZeneca Reaches $775 Million Settlement Resolving Ultomiris Patent Dispute

  • Post author:PacConAdmin
  • Post published:March 17, 2022
  • Post category:Drug Industry Daily

AstraZeneca (AZ) has agreed to pay Chugai Pharmaceutical $775 million to resolve allegations that AZ’s rare disease immunotherapy, Ultomiris (ravulizumab), infringed on the Tokyo-based company’s patents. Source: Drug Industry Daily

Continue ReadingAstraZeneca Reaches $775 Million Settlement Resolving Ultomiris Patent Dispute

Gilead Becomes 15th Major Drugmaker to Limit Its Participation in the 340B Drug Discount Program

  • Post author:PacConAdmin
  • Post published:March 17, 2022
  • Post category:Drug Industry Daily

Gilead Sciences has become the 15th major drugmaker to limit its involvement with the 30-year-old 340B Drug Discount Program that was designed to serve low-income patient populations in the U.S.…

Continue ReadingGilead Becomes 15th Major Drugmaker to Limit Its Participation in the 340B Drug Discount Program

New Alzheimer’s Prevention Trial Combines Anti-Tau and Antiamyloid Antibodies

  • Post author:PacConAdmin
  • Post published:March 17, 2022
  • Post category:Drug Industry Daily

Esai’s investigational anti-tau antibody E2841 grabbed some air time yesterday in Barcelona, Spain, with the first detailed look at a phase 2/3 study in people who are genetically predestined to…

Continue ReadingNew Alzheimer’s Prevention Trial Combines Anti-Tau and Antiamyloid Antibodies

Alnylam Pharmaceuticals Sues Pfizer and Moderna Over LNP Technology, Moderna Pushes Back

  • Post author:PacConAdmin
  • Post published:March 17, 2022
  • Post category:Drug Industry Daily

Alnylam Pharmaceuticals is suing both Pfizer and Moderna in separate suits, alleging that both companies’ COVID-19 vaccines infringe on one of Alnylam patents for technology that allows RNA-based therapeutics or…

Continue ReadingAlnylam Pharmaceuticals Sues Pfizer and Moderna Over LNP Technology, Moderna Pushes Back

New Jersey Compounding Pharmacy Cited for Lax Quality, Sterility

  • Post author:PacConAdmin
  • Post published:March 17, 2022
  • Post category:Drug Industry Daily

Drug compounding pharmacy Ideal Specialty Apothecary of Parsippany, N.J., has received a Form 483 detailing quality deficiencies observed during an FDA inspection from Sept. 13 through Nov. 18, 2021. Source:…

Continue ReadingNew Jersey Compounding Pharmacy Cited for Lax Quality, Sterility

Senate Finance Committee Examines High Prescription Drug Prices as Lawmakers Respond to PhRMA

  • Post author:PacConAdmin
  • Post published:March 16, 2022
  • Post category:Drug Industry Daily

Senators lambasted the pharmaceutical industry yesterday in a hearing by the Senate Finance Committee on the high price of drugs in the U.S. Source: Drug Industry Daily

Continue ReadingSenate Finance Committee Examines High Prescription Drug Prices as Lawmakers Respond to PhRMA

FDA Issues Warning Letter for Website Making Unapproved Hydroxychloroquine Claims

  • Post author:PacConAdmin
  • Post published:March 16, 2022
  • Post category:Drug Industry Daily

The FDA has sent a warning letter to Ivermectin24h.com, a website the agency said is marketing hydroxychloroquine as a COVID-19 treatment. Source: Drug Industry Daily

Continue ReadingFDA Issues Warning Letter for Website Making Unapproved Hydroxychloroquine Claims
  • Go to the previous page
  • 1
  • …
  • 276
  • 277
  • 278
  • 279
  • 280
  • 281
  • 282
  • …
  • 328
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.